Stocks · Healthcare · Biotechnology
Immunome, Inc. IMNM
$20.90 +0.05% Close, Oct 2, 2026 · NASDAQ · Market cap $2.00B
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 30.2% in a year.
- Over the past year the stock returned +84.3%, ahead of the S&P 500 by 69.2 percentage points.
- The company holds net cash of $213.1M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth accelerationBottom 8%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 24%
- Accruals (lower is better)Top 42%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 42%
- Free-cash-flow yieldBottom 36%
- EBITDA / enterprise valueBottom 33%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 11%
- 6-month returnBottom 38%
- 1-year return vs S&P 500Top 17%
- Distance from 52-week highTop 47%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 27%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 48%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 42%
- Maximum drawdown, 3 yearsBottom 33%
- Beta vs S&P 500 (lower is better)Bottom 29%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -63.3% | -100.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -63.3% | ↓ | Bottom 2% |
| Return on invested capital | -51.1% | — | Bottom 24% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -8.1%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -23.98%
- Shareholder yield
- -23.98%
- Share count change, 1 year
- +30.2%
- Share count change, 3-year CAGR
- +110.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -11.9%
- Average 2-day reaction, last 8
- -0.4%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $33.00
- Target vs current price
- +57.9%
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | -26.5% | +2.2% | +6.7% | +4.4% | — |
| May 12, 2026 | +20.0% | -1.3% | -13.5% | -20.0% | +12.3% |
| Mar 3, 2026 | -27.1% | -3.0% | -4.0% | -13.1% | -0.5% |
| Nov 6, 2025 | -14.0% | +1.0% | +13.6% | +30.9% | +75.7% |
| Aug 6, 2025 | +3.8% | -3.6% | -8.7% | -5.5% | +45.3% |
| May 12, 2025 | +21.2% | +6.4% | +8.0% | +24.3% | +40.2% |
| Mar 19, 2025 | -23.5% | +2.5% | -16.9% | -11.5% | +17.1% |
| Nov 13, 2024 | -30.0% | -7.2% | -24.8% | +12.4% | -17.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.65 | -$0.51 | -26.5% | — |
| May 12, 2026 | -$0.48 | -$0.60 | +20.0% | — |
| Mar 3, 2026 | -$0.75 | -$0.59 | -27.1% | — |
| Nov 6, 2025 | -$0.65 | -$0.57 | -14.0% | — |
| Aug 6, 2025 | -$0.50 | -$0.52 | +3.8% | $4.0M |
| May 12, 2025 | -$0.52 | -$0.66 | +21.2% | $2.9M |
| Mar 19, 2025 | -$0.84 | -$0.68 | -23.5% | $2.7M |
| Nov 13, 2024 | -$0.78 | -$0.60 | -30.0% | $2.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -10.97% | — | — | Bottom 36% |
| Earnings yield | -12.15% | — | — | Bottom 42% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +2.1%
- 200-day average slope (20 days)
- +2.2%
- Distance from 50-day average
- -17.2%
- Distance from 200-day average
- -8.2%
- RSI (14)
- 31.2
- Relative volume
- 0.88×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 51.2%
- Volatility vs own 5-year history
- 5th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.57
- Correlation with S&P 500
- 0.36
- Current drawdown from 1-year high
- -29.9%
- Maximum drawdown, 3 years
- -79.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 24, 2021 | Dec 30, 2022 | -94.9% | 467 days | Not yet recovered |
| Oct 8, 2020 | Dec 29, 2020 | -33.2% | 56 days | 13 days (Jan 19, 2021) |
| Feb 18, 2021 | Feb 23, 2021 | -26.9% | 3 days | 1 days (Feb 24, 2021) |
| Jan 25, 2021 | Jan 28, 2021 | -21.1% | 3 days | 3 days (Feb 2, 2021) |
| Feb 3, 2021 | Feb 5, 2021 | -12.1% | 2 days | 2 days (Feb 9, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $2.00B
- EPS, diluted (TTM)
- -$2.54
- Revenue (TTM)
- $0
- 52-week range
- $11.25 – $30.06
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $14.0M | $9.0M | $6.9M |
| Gross profit | $0 | $0 | $14.0M | $9.0M | $4.0M |
| Operating income | -$25.2M | -$36.9M | -$109.5M | -$305.8M | -$214.1M |
| Net income | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
| EPS (diluted) | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9M | $2.7M | $2.9M | $4.0M | $0 | $0 | $0 | $0 |
| Net income | -$47.1M | -$80.2M | -$41.6M | -$43.4M | -$57.5M | -$69.9M | -$53.8M | -$73.1M |
| EPS (diluted) | -$0.78 | -$1.28 | -$0.52 | -$0.50 | -$0.65 | -$0.76 | -$0.48 | -$0.65 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$18.2M | -$28.7M | -$7.6M | -$110.8M | -$190.9M |
| Capital expenditure | -$79,000 | -$248,000 | -$831,000 | -$53.5M | -$9.7M |
| Free cash flow | -$18.3M | -$28.9M | -$8.4M | -$164.3M | -$200.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $27.2M | $32,000 | $34,000 | $250.0M | $640.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $520.0M
- Total assets
- $565.4M
- Total liabilities
- $40.3M
- Total debt
- $4.6M
- Net debt
- -$213.1M
- Shareholders’ equity
- $525.1M
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 16,244,557
- Days to cover
- 20.63
- Change vs previous report
- +3.9%
FINRA short interest, settlement date Sep 15, 2026.